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Since 1976, most epidemiological studies about Ebola Hemor-
rhagic Fever have reported case fatality rate (CFR) of up to 90% 
(1). According to the report of WHO (1 August 2014) CFR is of 
55–60% (total number of cases 1,603 – deaths 887).
The WHO Report included data of confirmed, probable, sus-
pect, and new patients: 
•	 Confirmed:	1,009	cases	and	deaths	574	(CFR	56.9%)
•	 Probable:	416	cases	and	deaths	265	(CFR	63.4%)
•	 Suspect:	178	cases	and	deaths	48	(CFR	27%)
•	 New:	 163	 cases	 and	 deaths	 61	 (CFR	37.4%);	 too	 early	 to	
calculate CFR  
•	 Total:	1,603	cases	and	deaths	887	(CFR	55.3%)
Considering only confirmed and probable cases (1,426 cases 
and 839 deaths), CFR will be of 58.9% (2). CFR based on these 
numbers could not be trustworthy based on these numbers, 
however, this is the largest outbreak with valid number of cases 
we have. 
Of no doubt, we cannot jump to conclusions based on simple 
calculation of CFR, however, it raises an important question: 
why CFR in the current outbreak is much lower than previous 
outbreaks of Ebola Hemorrhagic Fever?
Several possible reasons could be the explanation: 
1. Virus strain. The current strain could be less virulent than 
strains isolated from previous outbreaks. 
2. The virus is adapting to the human host. Fruit bats are consid-
ered the natural hosts for Ebola virus.
3.	 Patient’s	immune	system	and	general	health.
4. Early detection of patients and commencement of supportive 
treatment. 
Currently there is no specific treatment for Ebola Hemorrhagic 
Fever. USA evacuated 2 American Ebola patients and they are 
currently receiving medical care at a hospital in Atlanta. Few days 
after Spain evacuated 2 Spanish patients (only 1 confirmed) to 
receive medical care at a specialized public hospital in Madrid.  
Nowadays,	only	supportive	care	is	available	(intravenous	flu-
ids;	blood	and	platelet	transfusions),	although	upcoming	human	
vaccine	trials	may	be	promising.	The	National	Institutes	of	Health	
(USA) will begin a human vaccine trial in September 2014 (3).
The prospects of transfusing blood or plasma from those 
patients who have recently recovered from Ebola virus infection 
seem promising. This could be an effective treatment as Ebola 
prophylaxis or for use in early onset of Ebola symptoms (4). 
Use of an experimental compound, referred to as BCX4430, 
was	recently	reported.	This	compound,	an	RNA-dependent	RNA	
polymerase inhibitor, has proven successful in a nonhuman pri-
mate model, whereby post exposure prophylaxis to BCX4430 
prevented	death	in	17	of	18	macaques	studied.	No	human	trials	
have yet been reported (5).
All public health professionals should collaborate to give basic 
preventive measures to the general population and to combat 
social alarm. We should avoid new false pandemic alarm like 
that	occurred	in	2009	with	influenza	A	(H1N1).	
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